Therapy-driven clonal dynamics in chronic lymphocytic leukemia
Understanding how leukemia cells evolve under different drugs helps doctors anticipate resistance and plan personalized therapy sequences.
This comprehensive review synthesizes current understanding of therapy-driven clonal evolution in CLL, covering resistance mechanisms from chemoimmunotherapy (TP53 aberrations) through BTK inhibitors (BTK/PLCG2 mutations) to emerging CAR-T and bispecific antibody contexts. It positions single-cell sequencing and integrative multi-omics as essential future tools for personalized therapeutic strategies.
What the study was
- Study design
- Narrative review
- Population
- CLL patients (review of existing literature)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Seminars in Cancer Biology
Why it surfaced
Comprehensive review from Karolinska/San Raffaele CLL groups; strong synthesis of resistance mechanisms relevant to evolving treatment landscape; no original data limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.